Supratherapeutic Response to Ezetimibe in a Statin Intolerant Patient
暂无分享,去创建一个
[1] R. Fresa,et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. , 2007, Atherosclerosis.
[2] J. Mckenney,et al. Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia , 2007, Pharmacotherapy.
[3] B. Hawes,et al. In Vivo Responsiveness to Ezetimibe Correlates with Niemann-Pick C1 Like-1 (NPC1L1) Binding Affinity: Comparison of Multiple Species NPC1L1 Orthologs , 2007, Molecular Pharmacology.
[4] E. Schadt,et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. , 2005, Genomics.
[5] S. Koshman,et al. Supratherapeutic Response to Ezetimibe Administered with Cyclosporine , 2005, The Annals of pharmacotherapy.
[6] P. McBride,et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. , 2005, Mayo Clinic proceedings.
[7] P. Ziajka,et al. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. , 2004, The American journal of cardiology.
[8] E. Nutescu,et al. Ezetimibe: A Selective Cholesterol Absorption Inhibitor , 2003, Pharmacotherapy.
[9] V. F. Mauro,et al. Ezetimibe for Management of Hypercholesterolemia , 2003, The Annals of pharmacotherapy.
[10] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.